Aeglea: Aeglea BioTherapeutics stock skyrockets as it boosts inflammatory bowel disease portfolio with Spyre Therapeutics acquisition
Aeglea Biotherapeutics (NASDAQ:AGLE) stock has skyrocketed on news that it is acquiring Spyre Therapeutics, a private biotechnology company focused on...
Read full article »
CEO
Aeglea is a pharmaceutical company that researches and develops enzyme-based therapeutics for the treatment of cancer and rare genetic diseases.
Read more